| . | n . | Values . | Reference Range . |
|---|---|---|---|
| Age, y | 32 | 30.9 (23.4–66.3) | |
| LH, U/L | 29 | 3.3 ± 1.5a | 2.0–9.0 |
| FSH, U/L | 29 | 8.2 ± 6.5 | 1.5–12.5 |
| FSH to LH ratio | 29 | 2.2 (1.8–2.7)a | 0.7–1.2 |
| T, nmol/L | 31 | 14.0 ± 5.0a | 8.0–31.0 |
| SHBG, nmol/L | 25 | 29.6 ± 15.5a | 20–55 |
| Inhibin B, ng/L | 20 | 253.6 ± 111.0 | 150–400 |
| Inhibin B to FSH ratio | 20 | 31.5 (17.2–55.6)a | 15–303 |
| AMH, μg/L | 21 | 7.0 (2.7–13.0) | 2.0–14.0 |
| Androstenedione, nmol/L | 24 | 6.3 (3.4–9.0) | 2.0–10.0 |
| DHEA, nmol/L | 20 | 9.7 (5.7–19.3)a | 7.0–60.0 |
| DHEAS, μmol/L | 22 | 3.3 (1.3–4.9)a | 2.0–15.0 |
| . | n . | Values . | Reference Range . |
|---|---|---|---|
| Age, y | 32 | 30.9 (23.4–66.3) | |
| LH, U/L | 29 | 3.3 ± 1.5a | 2.0–9.0 |
| FSH, U/L | 29 | 8.2 ± 6.5 | 1.5–12.5 |
| FSH to LH ratio | 29 | 2.2 (1.8–2.7)a | 0.7–1.2 |
| T, nmol/L | 31 | 14.0 ± 5.0a | 8.0–31.0 |
| SHBG, nmol/L | 25 | 29.6 ± 15.5a | 20–55 |
| Inhibin B, ng/L | 20 | 253.6 ± 111.0 | 150–400 |
| Inhibin B to FSH ratio | 20 | 31.5 (17.2–55.6)a | 15–303 |
| AMH, μg/L | 21 | 7.0 (2.7–13.0) | 2.0–14.0 |
| Androstenedione, nmol/L | 24 | 6.3 (3.4–9.0) | 2.0–10.0 |
| DHEA, nmol/L | 20 | 9.7 (5.7–19.3)a | 7.0–60.0 |
| DHEAS, μmol/L | 22 | 3.3 (1.3–4.9)a | 2.0–15.0 |
Abbreviation: AMH, anti-Müllerian hormone. Data are presented as median (interquartile range) or mean ± SD.
Different from population median at P < .05.
| . | n . | Values . | Reference Range . |
|---|---|---|---|
| Age, y | 32 | 30.9 (23.4–66.3) | |
| LH, U/L | 29 | 3.3 ± 1.5a | 2.0–9.0 |
| FSH, U/L | 29 | 8.2 ± 6.5 | 1.5–12.5 |
| FSH to LH ratio | 29 | 2.2 (1.8–2.7)a | 0.7–1.2 |
| T, nmol/L | 31 | 14.0 ± 5.0a | 8.0–31.0 |
| SHBG, nmol/L | 25 | 29.6 ± 15.5a | 20–55 |
| Inhibin B, ng/L | 20 | 253.6 ± 111.0 | 150–400 |
| Inhibin B to FSH ratio | 20 | 31.5 (17.2–55.6)a | 15–303 |
| AMH, μg/L | 21 | 7.0 (2.7–13.0) | 2.0–14.0 |
| Androstenedione, nmol/L | 24 | 6.3 (3.4–9.0) | 2.0–10.0 |
| DHEA, nmol/L | 20 | 9.7 (5.7–19.3)a | 7.0–60.0 |
| DHEAS, μmol/L | 22 | 3.3 (1.3–4.9)a | 2.0–15.0 |
| . | n . | Values . | Reference Range . |
|---|---|---|---|
| Age, y | 32 | 30.9 (23.4–66.3) | |
| LH, U/L | 29 | 3.3 ± 1.5a | 2.0–9.0 |
| FSH, U/L | 29 | 8.2 ± 6.5 | 1.5–12.5 |
| FSH to LH ratio | 29 | 2.2 (1.8–2.7)a | 0.7–1.2 |
| T, nmol/L | 31 | 14.0 ± 5.0a | 8.0–31.0 |
| SHBG, nmol/L | 25 | 29.6 ± 15.5a | 20–55 |
| Inhibin B, ng/L | 20 | 253.6 ± 111.0 | 150–400 |
| Inhibin B to FSH ratio | 20 | 31.5 (17.2–55.6)a | 15–303 |
| AMH, μg/L | 21 | 7.0 (2.7–13.0) | 2.0–14.0 |
| Androstenedione, nmol/L | 24 | 6.3 (3.4–9.0) | 2.0–10.0 |
| DHEA, nmol/L | 20 | 9.7 (5.7–19.3)a | 7.0–60.0 |
| DHEAS, μmol/L | 22 | 3.3 (1.3–4.9)a | 2.0–15.0 |
Abbreviation: AMH, anti-Müllerian hormone. Data are presented as median (interquartile range) or mean ± SD.
Different from population median at P < .05.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
